These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 36027720)

  • 21. 5-year retrospective analysis of patients with phenylketonuria (PKU) and hyperphenylalaninemia treated at two specialized clinics.
    Levy H; Lamppu D; Anastosoaie V; Baker JL; DiBona K; Hawthorne S; Lindenberger J; Kinch D; Seymour A; McIlduff M; Watling S; Vockley J
    Mol Genet Metab; 2020 Mar; 129(3):177-185. PubMed ID: 31883647
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recommendations on phenylketonuria in Turkey.
    Coşkun T; Çoker M; Mungan NÖ; Özel HG; Sivri HS
    Turk J Pediatr; 2022; 64(3):413-434. PubMed ID: 35899555
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Establishing core outcome sets for phenylketonuria (PKU) and medium-chain Acyl-CoA dehydrogenase (MCAD) deficiency in children: study protocol for systematic reviews and Delphi surveys.
    Potter BK; Hutton B; Clifford TJ; Pallone N; Smith M; Stockler S; Chakraborty P; Barbeau P; Garritty CM; Pugliese M; Rahman A; Skidmore B; Tessier L; Tingley K; Coyle D; Greenberg CR; Korngut L; MacKenzie A; Mitchell JJ; Nicholls S; Offringa M; Schulze A; Taljaard M;
    Trials; 2017 Dec; 18(1):603. PubMed ID: 29258568
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of national consensus statements on food labelling interpretation and protein allocation in a low phenylalanine diet for PKU.
    ; Evans S; Ford S; Adam S; Adams S; Ash J; Ashmore C; Caine G; Carruthers R; Cawtherley S; Chahal S; Clark A; Cochrane B; Daly A; Dines K; Dixon M; Dunlop C; Ellerton C; French M; Gaff L; Gingell C; Green D; Gribben J; Grimsley A; Hallam P; Hendroff U; Hill M; Hoban R; Howe S; Hunjan I; Kaalund K; Kelleher E; Khan F; Kitchen S; Lang K; Lowry S; Males J; Martin G; McStravick N; Micciche A; Newby C; Nicol C; Pereira R; Robertson L; Ross K; Simpson E; Singleton K; Skeath R; Stafford J; Terry A; Thom R; Tooke A; vanWyk K; White F; White L; MacDonald A
    Orphanet J Rare Dis; 2019 Jan; 14(1):2. PubMed ID: 30606267
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The European Phenylketonuria Guidelines and the challenges on management practices in Portugal.
    Sousa C; Almeida MF; Sousa Barbosa C; Martins E; Janeiro P; Tavares de Almeida I; MacDonald A; Rocha JC
    J Pediatr Endocrinol Metab; 2019 Jun; 32(6):623-629. PubMed ID: 31141484
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neurocognitive functioning in adults with phenylketonuria: results of a long term study.
    Weglage J; Fromm J; van Teeffelen-Heithoff A; Möller HE; Koletzko B; Marquardt T; Rutsch F; Feldmann R
    Mol Genet Metab; 2013; 110 Suppl():S44-8. PubMed ID: 24071437
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Uniformity of Food Protein Interpretation Amongst Dietitians for Patients with Phenylketonuria (PKU): 2020 UK National Consensus Statements.
    Evans S; Adam S; Adams S; Allen H; Ashmore C; Bailey S; Banks J; Churchill H; Cochrane B; Cook J; Dale C; Daly A; Dixon M; Dunlop C; Ellerton C; Emm A; Firman S; Ford S; French M; Gribben J; Grimsley A; Herlihy I; Hill M; Judd S; Lang K; Males J; McDonald J; McStravick N; Millington C; Newby C; Noble C; Pereira R; Pinto A; Robertson L; Robotham A; Ross K; Singleton K; Skeath R; Terry A; Van Wyk K; White F; White L; Wildgoose J; Woodall A; MacDonald A
    Nutrients; 2020 Jul; 12(8):. PubMed ID: 32722073
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metabolic Control of Patients with Phenylketonuria in a Portuguese Metabolic Centre Comparing Three Different Recommendations.
    Kanufre V; Almeida MF; Barbosa CS; Carmona C; Bandeira A; Martins E; Rocha S; Guimas A; Ribeiro R; MacDonald A; Pinto A; Rocha JC
    Nutrients; 2021 Sep; 13(9):. PubMed ID: 34578995
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence of comorbid conditions among adult patients diagnosed with phenylketonuria.
    Burton BK; Jones KB; Cederbaum S; Rohr F; Waisbren S; Irwin DE; Kim G; Lilienstein J; Alvarez I; Jurecki E; Levy H
    Mol Genet Metab; 2018 Nov; 125(3):228-234. PubMed ID: 30266197
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The management of transitional care of patients affected by phenylketonuria in Italy: Review and expert opinion.
    Biasucci G; Brodosi L; Bettocchi I; Noto D; Pochiero F; Urban ML; Burlina A
    Mol Genet Metab; 2022 Jun; 136(2):94-100. PubMed ID: 35589496
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expert opinion of an Italian working group on the assessment of cognitive, psychological, and neurological outcomes in pediatric, adolescent, and adult patients with phenylketonuria.
    Manti F; Caviglia S; Cazzorla C; Dicintio A; Pilotto A; Burlina AP
    Orphanet J Rare Dis; 2022 Dec; 17(1):443. PubMed ID: 36544165
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Management of adult patients with phenylketonuria: survey results from 24 countries.
    Trefz FK; van Spronsen FJ; MacDonald A; Feillet F; Muntau AC; Belanger-Quintana A; Burlina A; Demirkol M; Giovannini M; Gasteyger C
    Eur J Pediatr; 2015 Jan; 174(1):119-27. PubMed ID: 25480112
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Strategies to engage lost to follow-up patients with phenylketonuria in the United States: Best practice recommendations.
    Beazer J; Breck J; Eggerding C; Gordon P; Hacker S; Thompson A;
    Mol Genet Metab Rep; 2020 Jun; 23():100571. PubMed ID: 32140415
    [TBL] [Abstract][Full Text] [Related]  

  • 34. "MY PKU": increasing self-management in patients with phenylketonuria. A randomized controlled trial.
    Ten Hoedt AE; Hollak CE; Boelen CC; van der Herberg-van de Wetering NA; Ter Horst NM; Jonkers CF; Wijburg FA; Bosch AM
    Orphanet J Rare Dis; 2011 Jun; 6():48. PubMed ID: 21708003
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [International Consensus Statement for the Screening, Diagnosis, and Treatment of Adolescents with Concurrent Attention-Deficit/Hyperactivity Disorder and Substance Use Disorder].
    Özgen H; Spijkerman R; Noack M; Holtmann M; Schellekens ASA; van de Glind G; Banaschewski T; Barta C; Begeman A; Casas M; Crunelle CL; Daigre Blanco C; Dalsgaard S; Demetrovics Z; den Boer J; Dom G; Eapen V; Faraone SV; Franck J; González RA; Grau-López L; Groenman AP; Hemphälä M; Icick R; Johnson B; Kaess M; Kapitány-Fövény M; Kasinathan JG; Kaye SS; Kiefer F; Konstenius M; Levin FR; Luderer M; Martinotti G; Matthys FIA; Meszaros G; Moggi F; Munasur-Naidoo AP; Post M; Rabinovitz S; Ramos-Quiroga JA; Sala R; Shafi A; Slobodin O; Staal WG; Thomasius R; Truter I; van Kernebeek MW; Velez-Pastrana MC; Vollstädt-Klein S; Vorspan F; Young JT; Yule A; van den Brink W; Hendriks V
    Z Kinder Jugendpsychiatr Psychother; 2021 Jan; 50(1):54-67. PubMed ID: 34397296
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of phenylketonuria for optimal outcome: a review of guidelines for phenylketonuria management and a report of surveys of parents, patients, and clinic directors.
    Wappner R; Cho S; Kronmal RA; Schuett V; Seashore MR
    Pediatrics; 1999 Dec; 104(6):e68. PubMed ID: 10586002
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A non-interventional observational study to identify and validate clinical outcome assessments for adults with phenylketonuria for use in clinical trials.
    Burton BK; Skalicky A; Baerwald C; Bilder DA; Harding CO; Ilan AB; Jurecki E; Longo N; Madden DT; Sivri HS; Wilcox G; Thomas J; Delaney K
    Mol Genet Metab Rep; 2021 Dec; 29():100810. PubMed ID: 34815941
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The management of phenylketonuria in adult patients in Italy: a survey of six specialist metabolic centers.
    Burlina A; Leuzzi V; Spada M; Carbone MT; Paci S; Tummolo A
    Curr Med Res Opin; 2021 Mar; 37(3):411-421. PubMed ID: 33222540
    [TBL] [Abstract][Full Text] [Related]  

  • 39. International Consensus Statement for the Screening, Diagnosis, and Treatment of Adolescents with Concurrent Attention-Deficit/Hyperactivity Disorder and Substance Use Disorder.
    Özgen H; Spijkerman R; Noack M; Holtmann M; Schellekens ASA; van de Glind G; Banaschewski T; Barta C; Begeman A; Casas M; Crunelle CL; Daigre Blanco C; Dalsgaard S; Demetrovics Z; den Boer J; Dom G; Eapen V; Faraone SV; Franck J; González RA; Grau-López L; Groenman AP; Hemphälä M; Icick R; Johnson B; Kaess M; Kapitány-Fövény M; Kasinathan JG; Kaye SS; Kiefer F; Konstenius M; Levin FR; Luderer M; Martinotti G; Matthys FIA; Meszaros G; Moggi F; Munasur-Naidoo AP; Post M; Rabinovitz S; Ramos-Quiroga JA; Sala R; Shafi A; Slobodin O; Staal WG; Thomasius R; Truter I; van Kernebeek MW; Velez-Pastrana MC; Vollstädt-Klein S; Vorspan F; Young JT; Yule A; van den Brink W; Hendriks V
    Eur Addict Res; 2020; 26(4-5):223-232. PubMed ID: 32634814
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of phenylalanine on cognitive, cerebral, and neurometabolic parameters in adult patients with phenylketonuria (the PICO study): a randomized, placebo-controlled, crossover, noninferiority trial.
    Trepp R; Muri R; Abgottspon S; Bosanska L; Hochuli M; Slotboom J; Rummel C; Kreis R; Everts R
    Trials; 2020 Feb; 21(1):178. PubMed ID: 32054509
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.